secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001815776-26-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M
--------------------------------------------------------------------------------

- Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.
- Net loss $35.9M ($1.16 per share) for Q4 2025 vs $12.7M in Q4 2024; cash $292.3M at year-end.
- Over 6,500 unique prescribers in Q4, on pace for 10,000+ through Q1 2026; >55% wrote multiple times.
- Sales force expanding from 88 to 117 territories in Q2 2026; MAA submitted to EMA in March 2026.
- Launched 'Make it VIZZable' DTC campaign with Sarah Jessica Parker; website traffic up 10x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/0001815776-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/lenz-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001815776-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer